Health insurance; prohibit modifications on renewal of covered and prescribed prescription drug's contracted benefit level.
HB93 would prohibit most health insurance plans and related coverage arrangements in Mississippi from changing an insured’s contracted benefit level for a prescription drug at renewal if the drug was covered in the immediately preceding plan year and was prescribed during that year for a medical condition or mental illness. The protection applies when the insured remained covered through renewal and the prescribing provider, in consultation with the patient, determines the drug is the most appropriate course of treatment.
The bill specifically bars a range of common coverage changes for those drugs, including removing the drug from a formulary, adding prior authorization, imposing or tightening quantity limits, requiring step therapy, moving the drug to a higher cost-sharing tier, increasing out-of-pocket costs, or reducing the maximum drug coverage amount. It applies to individual and group health insurance policies, nonprofit health service contracts, HMOs, self-insured group arrangements to the extent allowed by federal law, and managed care entities, beginning July 1, 2025.
HB93 would amend Mississippi insurance law to create a continuity-of-coverage rule for certain prescription drugs, limiting insurers’ ability to alter coverage terms at renewal for ongoing treatment. The practical effect would be to preserve access and cost-sharing terms for patients already using a covered medication, while still allowing insurers to make changes for drugs that are deemed clinically unsafe by the FDA, discontinued by the manufacturer, or removed from the market. The bill would affect health insurers, HMOs, nonprofit health plans, self-insured employer plans where not preempted by federal law, and Mississippi residents covered under those plans.
The available context shows no recorded committee debate, votes, or amendments, so there is no documented public sentiment from legislative proceedings. Based on the bill’s structure and caption, the measure appears designed to protect patients from disruptive midstream coverage changes for needed medications, which typically draws support from patient advocates and some providers. At the same time, the bill would likely be viewed cautiously by insurers and plan administrators because it restricts formulary management and utilization controls.
The main point of contention is the balance between patient continuity of care and insurer flexibility to manage drug costs and formularies. Supporters would likely emphasize that patients should not lose access to a medication that is already working, especially for chronic conditions or mental illness. Opponents or concerned stakeholders may argue that the bill limits tools such as prior authorization, step therapy, tiering, and cost-sharing adjustments that insurers use to control premiums and encourage cost-effective prescribing. The bill attempts to narrow that conflict by preserving exceptions for FDA safety concerns, manufacturer discontinuance, or market removal.